Abstract | BACKGROUND: METHODS: We retrospectively analyzed the clinical data of children diagnosed with DIPG at our center (Pediatric Hospital "Regina Margherita," Turin, Italy) between 1999 and 2013. Progression-free survival (PFS) and overall survival (OS) were used to describe the outcomes. RESULTS: Twenty-four children were included in our report. Patients diagnosed before March 2003 (n = 12) were treated with XRT and vincristine (VCR); the remaining 12 patients received XRT and temozolomide (TMZ). Progression-free survival was 18.8 % at 1 year (SE = 7.6 %), while overall survival was 44.1 % at 1 year (SE = 9.9 %). Median PFS was 8.1 months, whereas median OS was 11.2 months. No statistically significant difference in PFS or OS was evidenced between the two treatment groups. CONCLUSION:
Radiotherapy followed by VCR or TMZ allows obtaining results that are in line with previous reports, with no advantages over other similar treatment schedules. DIPGs are challenging tumors with a dismal outcome. Further research and newer therapies are urgently needed in order to achieve improvements in survival.
|
Authors | Stefano Gabriele Vallero, Daniele Bertin, Maria Eleonora Basso, Laura Stefania Pittana, Anna Mussano, Franca Fagioli |
Journal | Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
(Childs Nerv Syst)
Vol. 30
Issue 6
Pg. 1061-6
(Jun 2014)
ISSN: 1433-0350 [Electronic] Germany |
PMID | 24420674
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents, Alkylating
- Dacarbazine
- Temozolomide
|
Topics |
- Adolescent
- Antineoplastic Agents, Alkylating
- Brain Stem Neoplasms
(diagnosis, mortality, therapy)
- Child
- Dacarbazine
(analogs & derivatives, therapeutic use)
- Female
- Glioma
(diagnosis, mortality, therapy)
- Humans
- Male
- Pons
(pathology)
- Retrospective Studies
- Survival Analysis
- Temozolomide
|